KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC) — Richard S. Finn (2017) | RDL Network
Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho-Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Ann‐Lii Cheng
Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, E. Chen, A.B. Siegel, Andrew X. Zhu, Ann‐Lii Cheng
Discussion(0)
No comments yet. Be the first to comment.